This report was first published by Endpoints News. To see the original version, click here
It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for recent examples).
But two cancer biologists — Aaron Ring at the Fred Hutchinson Cancer Center and Aashish Manglik at UCSF — believed they could go one layer deeper than others. Even within a single protein target, there could be different ways for a drug to attach. They just needed a systematic way to seek out those small bits on a protein that could be even more specific cancer drug targets.
您已阅读20%（632字），剩余80%（2528字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。